Insider Transactions in Q3 2024 at Arcutis Biotherapeutics, Inc. (ARQT)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 24
2024
|
David Joseph Topper Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,626
-6.84%
|
$104,634
$9.48 P/Share
|
|
Sep 21
2024
|
David Joseph Topper Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+26.09%
|
-
|
|
Sep 03
2024
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-4.95%
|
$100,000
$10.77 P/Share
|
|
Aug 19
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
1,728
-0.88%
|
$13,824
$8.29 P/Share
|
|
Aug 02
2024
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
14,487
-1.68%
|
$130,383
$9.02 P/Share
|
|
Aug 02
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
13,206
-6.29%
|
$118,854
$9.02 P/Share
|
|
Aug 02
2024
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
5,220
-2.77%
|
$46,980
$9.02 P/Share
|
|
Aug 01
2024
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.71%
|
$90,000
$9.87 P/Share
|
|
Aug 01
2024
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,614
+3.42%
|
$6,614
$1.68 P/Share
|
|
Jul 01
2024
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.25%
|
$90,000
$9.31 P/Share
|
|
Jul 01
2024
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.59%
|
$10,000
$1.68 P/Share
|